“Several” medications marketed by Danish pharmaceutical company Novo Nordisk raised a thyroid cancer safety signal by the European Medicines Agency in May including semaglutide, which is used to manufacture “popular” medications Ozempic and Wegovy, reports Nikolaj Skydsgaard for Reuters. “Such a signal from the EMA does not mean that the medicine is the cause of any reported adverse events,” noted Reuters.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NVO:
- Novo Nordisk Takes Legal Route to Crack Down on Copycat Drugs
- Novo Nordisk sues spas, clinics selling ‘custom-made’ Ozempic, WSJ reports
- Novo Nordisk price target raised to DKK 1,150 from DKK 950 at Berenberg
- Cantor Fitzgerald biotech/biopharma to hold analyst/industry conference call
- Cantor Fitzgerald biotech/biopharma to hold a luncheon meeting